Although they fall outside official testing guidelines for lung cancer, people who have smoked at all in their lifetime could still be at risk for the disease. Researchers propose a biomarker test for 4 proteins could identify more individuals that could benefit from subsequent screening.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
Recent findings identified interactions between the EGFR and estrogen receptor signaling pathways, which could potentially modify outcomes in non-small cell lung cancer.
Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic SitesJune 22, 2018
In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
The researchers argue that upfront next-generation sequencing should be the new standard of care.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
"BRAF-mutated NSCLC represents an emerging targetable entity among the scenario of oncogene-driven NSCLC."
James L. Gulley, MD, PhD, FACP, discusses his findings at ASCO 2018 meeting.
EGFR tyrosine kinase inhibitor monotherapy has improved progression-free survival (PFS) but not overall survival (OS) compared with chemotherapy in non-small cell lung cancer.
Recent studies have explored the potential of combination therapy with EGFR-TKIs and VEGF-inhibitors for patients with EGFR-positive non-small cell lung cancer.
Danny Rischin, MBBS, FRACP, MD, speaks at the American Society of Clinical Oncology (ASCO) 2018 meeting.
Enriqueta Felip, MD, PhD, discusses her findings at the ASCO 2018 meeting in Chicago.
Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer given web-mediated follow-up.
Current literature reflects estimates, but not actual rates, of low-dose computed tomography adherence across the United States.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
Some figures show that incidence of brain metastasis is approximately 30% 2 years after being diagnosed with non-small cell lung cancer.
The phase 3 study found the combination effective, regardless of tumor proportion score.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
PD-1/PD-L1 ICI can offer remarkable benefits as first- and second-line treatments for NSCLC, but 80% of patients do not respond to immunotherapy, and many of those who do respond eventually see their cancers acquire drug resistance.
Researchers accessed the French National Hospital registry and obtained the records of 64,950 patients who died of metastatic NSCLC between 2010 and 2013.
Asthma inhalation therapies including exercise induced bronchospasm (EIB) and asthma maintenance dosing.
Non-small cell lung cancer largely remains incurable and is associated with high symptom burden and reduced quality of life.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Researchers are evaluating whether CAR-T cell immunotherapy that targets mesothelin is safe and effective among patients with mesothelin-expressing tumors.
Access treatment options for mesothelioma in this detailed drug regimen, which includes agents such as pemetrexed + cisplatin and more.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Massage and Cancer
- Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer
- Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers
- Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma
- Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer